These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31102655)

  • 1. CRISPR/Cas: An intriguing genomic editing tool with prospects in treating neurodegenerative diseases.
    Rahman S; Datta M; Kim J; Jan AT
    Semin Cell Dev Biol; 2019 Dec; 96():22-31. PubMed ID: 31102655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of the gene editing tool, CRISPR-Cas9, for treating neurodegenerative diseases.
    Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
    Neurochem Int; 2018 Jan; 112():187-196. PubMed ID: 28732771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of combined viral transduction and CRISPR/Cas9 gene editing in treating neurodegenerative diseases.
    Kuruvilla J; Sasmita AO; Ling APK
    Neurol Sci; 2018 Nov; 39(11):1827-1835. PubMed ID: 30076486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9 Technology as a Modern Genetic Manipulation Tool for Recapitulating of Neurodegenerative Disorders in Large Animal Models.
    Barazesh M; Mohammadi S; Bahrami Y; Mokarram P; Morowvat MH; Saidijam M; Karimipoor M; Kavousipour S; Vosoughi AR; Khanaki K
    Curr Gene Ther; 2021; 21(2):130-148. PubMed ID: 33319680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Versatile and multifaceted CRISPR/Cas gene editing tool for plant research.
    Pandey PK; Quilichini TD; Vaid N; Gao P; Xiang D; Datla R
    Semin Cell Dev Biol; 2019 Dec; 96():107-114. PubMed ID: 31022459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and application of CRISPR/Cas9 technologies in genomic editing.
    Zhang C; Quan R; Wang J
    Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders.
    Raikwar SP; Kikkeri NS; Sakuru R; Saeed D; Zahoor H; Premkumar K; Mentor S; Thangavel R; Dubova I; Ahmed ME; Selvakumar GP; Kempuraj D; Zaheer S; Iyer SS; Zaheer A
    J Neuroimmune Pharmacol; 2019 Dec; 14(4):608-641. PubMed ID: 31011884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Editing With TALEN and CRISPR/Cas in Rice.
    Bi H; Yang B
    Prog Mol Biol Transl Sci; 2017; 149():81-98. PubMed ID: 28712502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-cas gene-editing as plausible treatment of neuromuscular and nucleotide-repeat-expansion diseases: A systematic review.
    Babačić H; Mehta A; Merkel O; Schoser B
    PLoS One; 2019; 14(2):e0212198. PubMed ID: 30794581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress of CRISPR-Cas Based Genome Editing in Photosynthetic Microbes.
    Naduthodi MIS; Barbosa MJ; van der Oost J
    Biotechnol J; 2018 Sep; 13(9):e1700591. PubMed ID: 29396999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing CRISPR-Cas systems for bacterial genome editing.
    Selle K; Barrangou R
    Trends Microbiol; 2015 Apr; 23(4):225-32. PubMed ID: 25698413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precise editing of plant genomes - Prospects and challenges.
    Satheesh V; Zhang H; Wang X; Lei M
    Semin Cell Dev Biol; 2019 Dec; 96():115-123. PubMed ID: 31002868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Gene Manipulation in Plants Using the CRISPR/Cas Technology.
    Zhang D; Li Z; Li JF
    J Genet Genomics; 2016 May; 43(5):251-62. PubMed ID: 27165865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR-Cas System: History and Prospects as a Genome Editing Tool in Microorganisms.
    Javed MR; Sadaf M; Ahmed T; Jamil A; Nawaz M; Abbas H; Ijaz A
    Curr Microbiol; 2018 Dec; 75(12):1675-1683. PubMed ID: 30078067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Research Progress on Application of CRISPR/Cas Genome Editing Technology in Hematological Diseases -Review].
    Xin LY; Liu AF; Zhong SS; Chen YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1284-8. PubMed ID: 27531817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of the CRISPR/Cas System for Generation of Pathogen-Resistant Plants.
    Makarova SS; Khromov AV; Spechenkova NA; Taliansky ME; Kalinina NO
    Biochemistry (Mosc); 2018 Dec; 83(12):1552-1562. PubMed ID: 30878030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR-Cas immunity, DNA repair and genome stability.
    Cubbon A; Ivancic-Bace I; Bolt EL
    Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30209206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-Enabled Tools for Engineering Microbial Genomes and Phenotypes.
    Tarasava K; Oh EJ; Eckert CA; Gill RT
    Biotechnol J; 2018 Sep; 13(9):e1700586. PubMed ID: 29917318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The CRISPR-Cas system: beyond genome editing].
    Croteau FR; Rousseau GM; Moineau S
    Med Sci (Paris); 2018 Oct; 34(10):813-819. PubMed ID: 30451675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the potential of genome editing CRISPR-Cas9 technology.
    Singh V; Braddick D; Dhar PK
    Gene; 2017 Jan; 599():1-18. PubMed ID: 27836667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.